Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ozanimod
Drug ID BADD_D02580
Description Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.[L12573,L12582] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting.[A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Indications and Usage Ozanimod is indicated for adults in the treatment of relapsing forms of MS, which may include relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive MS.[L12582]
Marketing Status approved; investigational
ATC Code L04AA38
DrugBank ID DB12612
KEGG ID D10968
MeSH ID C000607776
PubChem ID 52938427
TTD Drug ID D07EDB
NDC Product Code Not Available
UNII Z80293URPV
Synonyms ozanimod | RPC1063
Chemical Information
Molecular Formula C23H24N4O3
CAS Registry Number 1306760-87-1
SMILES CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diabetes mellitus14.06.01.001; 05.06.01.0010.000723%Not Available
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.0040.000241%Not Available
Diplopia06.02.06.002; 17.17.01.0050.001640%Not Available
Discomfort08.01.08.0030.001061%Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.001302%
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.0060.042050%
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.0040.001230%Not Available
Drug ineffective08.06.01.0060.057409%Not Available
Dry mouth07.06.01.0020.002459%
Dry throat22.12.03.005; 07.06.01.0050.000820%Not Available
Dysarthria19.19.03.001; 17.02.08.0010.001640%
Dyspepsia07.01.02.0010.002532%
Dyspnoea02.11.05.003; 22.02.01.0040.016540%
Emotional disorder19.04.02.0050.001760%Not Available
Extrasystoles02.03.02.0030.000651%Not Available
Eye disorder06.08.03.0010.001881%Not Available
Eye pain06.08.03.0020.002773%
Faeces discoloured07.01.03.0020.001230%Not Available
Fatigue08.01.01.0020.072261%
Feeling abnormal08.01.09.0140.015889%Not Available
Feeling cold08.01.09.0080.000820%Not Available
Feeling jittery08.01.09.0160.001640%Not Available
Flatulence07.01.04.0020.002459%
Frequent bowel movements07.02.04.0020.001061%Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.0020.012610%
Gallbladder disorder09.03.02.0010.000772%Not Available
Gastrooesophageal reflux disease07.02.02.0030.001760%
Gastrointestinal disorder07.11.01.0010.004292%Not Available
Gastrointestinal pain07.01.05.0050.000530%
Gingival bleeding24.07.02.010; 07.09.07.0010.000820%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages